Next Article in Journal
Salivary Gland Extract from Aedes aegypti Improves Survival in Murine Polymicrobial Sepsis through Oxidative Mechanisms
Previous Article in Journal
The Relationship between Turgor Pressure Change and Cell Hydraulics of Midrib Parenchyma Cells in the Leaves of Zea mays
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessReview
Cells 2018, 7(10), 181; https://doi.org/10.3390/cells7100181

Is there a Chance to Promote Arteriogenesis by DPP4 Inhibitors Even in Type 2 Diabetes? A Critical Review

1
MedGenome Labs Ltd., Bangalore, Karnataka 560099, India
2
School of Chemical Biotechnology, SASTRA University, Thanjavur 613401, India
3
Walter-Brendel-Centre of Experimental Medicine, University Hospital, LMU Munich, 80336 Munich, Germany
*
Author to whom correspondence should be addressed.
Received: 13 August 2018 / Revised: 8 October 2018 / Accepted: 18 October 2018 / Published: 22 October 2018
Full-Text   |   PDF [1148 KB, uploaded 23 October 2018]   |  

Abstract

Cardiovascular diseases (CVD) are still the prevailing cause of death not only in industrialized countries, but even worldwide. Type 2 diabetes mellitus (type 2 DM) and hyperlipidemia, a metabolic disorder that is often associated with diabetes, are major risk factors for developing CVD. Recently, clinical trials proved the safety of gliptins in treating patients with type 2 DM. Gliptins are dipeptidyl-peptidase 4 (DPP4/CD26) inhibitors, which stabilize glucagon-like peptide-1 (GLP-1), thereby increasing the bioavailability of insulin. Moreover, blocking DPP4 results in increased levels of stromal cell derived factor 1 (SDF-1). SDF-1 has been shown in pre-clinical animal studies to improve heart function and survival after myocardial infarction, and to promote arteriogenesis, the growth of natural bypasses, compensating for the function of an occluded artery. Clinical trials, however, failed to demonstrate a superiority of gliptins compared to placebo treated type 2 DM patients in terms of cardiovascular (CV) outcomes. This review highlights the function of DPP4 inhibitors in type 2 DM, and in treating cardiovascular diseases, with special emphasis on arteriogenesis. It critically addresses the potency of currently available gliptins and gives rise to hope by pointing out the most relevant questions that need to be resolved. View Full-Text
Keywords: cardiovascular disease (CVD); arteriogenesis; diabetes mellitus; dipeptidyl-peptidase-4 (DPP4) inhibitors; stromal-cell-derived factor-1 (SDF-1); gliptins cardiovascular disease (CVD); arteriogenesis; diabetes mellitus; dipeptidyl-peptidase-4 (DPP4) inhibitors; stromal-cell-derived factor-1 (SDF-1); gliptins
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Vedantham, S.; Kluever, A.-K.; Deindl, E. Is there a Chance to Promote Arteriogenesis by DPP4 Inhibitors Even in Type 2 Diabetes? A Critical Review. Cells 2018, 7, 181.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top